Wednesday, July 8, 2026

pharma · Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis (NASH) Cirrhosis · MDGL

Madrigal Pharmaceuticals EU

Madrigal Pharmaceuticals EU clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US HQ
2016 Founded
1,071 Employees
Public company Type
MDGL · NYSE Ticker
Company details
Status
Public
HQ
200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
Founded
2016
Employees
1,071
Programs
16
Drugs
11
Patents
26
Intelligence · Clinical Programs

Madrigal Pharmaceuticals EU projects

16 ClinicalTrials.gov programs sponsored by Madrigal Pharmaceuticals EU.

Madrigal Pharmaceuticals EU has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial
  2. MGL-3196-11

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial
  3. MGL-3196-19

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial
  4. Placebo

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule completed

    1 trial
  5. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    NASH

    phase 3 small molecule active

    1 trial
  6. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule active

    1 trial
  7. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial
  8. MGL-3196 (resmetirom)

    Madrigal Pharmaceuticals EU Limited

    Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial
  9. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial
  10. 100 mg Resmetirom Tablet

    Madrigal Pharmaceuticals EU Limited

    Renal Impairment

    phase 1 small molecule completed

    1 trial
  11. Atorvastatin

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    1 trial
  12. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial
  13. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    3 trials
  14. MGL-3196 Tablet

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    1 trial
  15. Placebo

    Madrigal Pharmaceuticals EU Limited

    Drug Safety

    phase 1 small molecule completed

    2 trials
  16. Simvastatin

    Madrigal Pharmaceuticals EU Limited

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Madrigal Pharmaceuticals EU have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.